







Ⅷ. (3年間の研究成果の)概要図等

※ポンチ絵等でわかりやすく簡潔に説明してください。



## ●研究代表者の研究歴等

※研究代表者に関するもののみを記載してください。(研究代表者には下線をつけて下さい)

### ・過去に所属した研究機関の履歴

- ・昭和61年～平成2年 国家公務員共済組合連合会虎の門病院内科  
消化器内科学(肝臓病学)に関する臨床研究を行った。
- ・平成2年～平成12年 国家公務員共済組合連合会虎の門病院内科 医長  
消化器内科学(肝臓病学)に関する臨床研究を行いつつ、肝炎ウイルスに関する分子生物学的研究を行った。
- ・平成12年9月～文部科学教官教授(広島大学内科学第一講座)  
消化器内科、循環器内科に関する診療、臨床研究を行いつつ、肝炎ウイルスに関する分子生物学的研究、ヒトの遺伝素因と疾患に関する研究、動物を用いた肝炎ウイルス肝炎モデルに関する研究を開始した。
- ・平成14年4月～広島大学大学院・医歯薬学総合研究科・創生医科学専攻・先進医療開発科学講座・分子病態制御内科学(旧内科学第一講座)教授  
消化器内科、循環器内科に関する診療、臨床研究を行いつつ、肝炎ウイルスに関する分子生物学的研究、ヒトの遺伝素因と疾患に関する研究、動物を用いた肝炎ウイルス肝炎モデルに関する研究をさらに展開している。

### ・主な共同研究者(又は指導を受けた研究者)

- ・指導を受けた研究者:熊田博光
- ・共同研究者:中村祐輔[シカゴ大学],松浦善治[大阪大学微生物学研究所],脇田隆字[国立感染症研究所],溝上雅史[国立肝炎免疫センター],金子周一[金沢大学],高倉喜信[京都大学],Jia-Horng Kao[National Taiwan University], Jake Liang[NIH], Susan Uprichard[Loyola University], Harel Dahari[Loyola University].

### ・主な研究課題

1. B型肝炎ウイルスの増殖に関する研究
2. B型慢性肝炎の治療に関する研究
3. C型肝炎ウイルスの増殖とインターフェロン治療効果との関連の研究
4. C型肝炎ウイルスの genotype に関する研究
5. 肝細胞癌の治療と再発防止に関する研究
6. 消化器癌の形態学的、分子病理学的研究
7. 内科学(消化器内科学)に関する研究

### ・これまでの研究実績

※研究代表者の本研究の成果以外の実績も記載してください。

(成果概要Ⅷと重複するものや本研究成果によるものは、**太字・斜体**文字で記載してください)

※発表文献名・学協会誌名・発表年(西暦)、知的財産権の取得及び申請状況、研究課題の実施を通じた政策提言(寄与した指針又はガイドライン等)のうち、主なものを選択し、直近年度から順に記載してください。

- (1) Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, Chayama K. Differences in serum microRNA profiles in hepatitis B and C virus infection. *J Infect.* 2014; in press.
- (2) Onitake T, Ueno Y, Tanaka S, Sagami S, Hayashi R, Nagai K, Hide M and Chayama K. Pulverized konjac glucomannan ameliorates oxazolone-induced colitis in mice. *Eur J Nutr.* 2014; in press.
- (3) Kan H, Yamagishi SI, Ojima A, Fukami K, Ueda S, Takeuchi M, Hyogo H, Aikata H and Chayama K. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma. *J Clin Lab Anal.* 2014; in press.

- (4) Hara Y, Yanatori I, Ikeda M, Kiyokage E, Nishina S, Tomiyama Y, Toida K, Kishi F, Kato N, Imamura M, **Chayama K** and Hino K. Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization. *Am J Pathol.* 2014; 184: 3026–3039.
- (5) **Chayama K**, Mitsui F and Hayes CN. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. *Expert Rev Gastroenterol Hepatol.* 2014; 41649.
- (6) Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, **Chayama K**, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I and Okanoue T. Efficacy of Telaprevir-based Therapy for Difficult-to-treat Patients with Genotype 2 Chronic Hepatitis C in Japan. *Hepatol Res.* 2014; in press.
- (7) Shakado S, Sakisaka S, Okanoue T, **Chayama K**, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seike M, Ueno Y and Kumada H. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. *Hepatol Res.* 2014; 44: 983–992.
- (8) Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Oda N, Hidaka T, Kihara Y, **Chayama K**, Goto C, Aibara Y, Noma K, Takeuchi M, Matsui T, Yamagishi SI, Higashi Y. Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is A Predictor of Endothelial Function. *Diabetes Care.* 2014; in press.
- (9) Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K and **Chayama K**. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of RECIST and tumor markers. *J Gastroenterol Hepatol.* 2014; in press.
- (10) Tanaka Y, Ohira M, Tashiro H, Imamura M, **Chayama K** and Ohdan H. Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. *Hum Immunol.* 2014; 75: 1259–67.
- (11) Hayes CN and **Chayama K**. Emerging treatments for chronic hepatitis C. *J Formos Med Assoc.* 2014; in press.
- (12) Takahashi S, Kimura T, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y, Doi Y, Kaneyasu Y, Murakami Y, Honda Y, Aikata H, **Chayama K** and Nagata Y. Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma. *Hepatol Res.* 2014; 44: E273–278.
- (13) Miwata T, Hiyama T, Quach D, Le H, Hua H, Oka S, Tanaka S, Arihiro K, **Chayama K**. Differences in K-ras and mitochondrial DNA mutations and microsatellite instability between colorectal cancers of Vietnamese and Japanese patients. *BMC Gastroenterol.* 2014; in press.
- (14) Kawaoka T, Takahashi S, Kawakami Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Aikata H, Ishiyama K, Tashiro H, Ohdan H, Tanaka J, **Chayama K**. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. *Hepatol Res.* 2014; in press.
- (15) Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, Kenjo M, Murakami Y, Honda Y, Kakizawa H, Awai K, **Chayama K** and Nagata Y. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. *Hepatol Res.* 2014; in press.

- (16) Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H and **Chayama K**. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. *J Viral Hepat.* 2014; 21: 348–356.
- (17) Naeshiro N, Aikata H, Kakizawa H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Ohno A, Miyaki D, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Awai K and **Chayama K**. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. *J Gastroenterol Hepatol.* 2014; 29: 1035–1042.
- (18) Aoe M, Shimada A, Muraoka M, Washio K, Nakamura Y, Takahashi T, Imada M, Watanabe T, Okada K, Nishiuchi R, Miyamura T, **Chayama K**, Shibakura M, Oda M and Morishima T. ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases. *Int J Hematol.* 2014; 99: 609–615.
- (19) Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H and **Chayama K**. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. *Hepatogastroenterology.* 2014; 61: 323–328.
- (20) Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K and **Chayama K**. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease. *Hepatol Res.* 2014; in press.
- (21) Ishitobi T, Hyogo H, Kan H, Hiramatsu A, Arihiro K, Aikata H and **Chayama K**. Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease. *Hepatol Res.* 2014; in press.
- (22) Kajikawa M, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, **Chayama K**, Nakashima A, Goto C, Noma K and Higashi Y. Borderline ankle-brachial index value of 0.91–0.99 is associated with endothelial dysfunction. *Circ J.* 2014; 78: 1740–1745.
- (23) Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, Murakami E, Kawaoka T, Tsuge M, Aikata H, Miki D, Ochi H, Matsui H, Kanai A, Inaba T and **Chayama K**. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. *J Viral Hepat.* 2014; in press.
- (24) Akamatsu S, Hayes CN, Tsuge M, Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, **Chayama K** and Hiroshima Liver Study G. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. *J Viral Hepat.* 2014; in press.
- (25) Ochi H, Miki D, Hayes CN, Abe H, Hayashida Y, Kubo M and **Chayama K**. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. *J Gen Virol.* 2014; 95: 1297–1306.
- (26) Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K and **Chayama K**. Role of 3-D conformal radiotherapy for major portal vein tumor

- thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. *Hepatol Res.* 2014; in press.
- (27) Shahidi M, Tay ES, Read SA, Ramezani-Moghadam M, Chayama K, George J and Douglas MW. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agents. *J Gen Virol.* 2014; 95: 2468–79.
- (28) Honda Y, Kawaoka T, Aikata H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Naeshiro N, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Arihiro K and Chayama K. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report. *Hepatol Res.* 2014; in press.
- (29) Tanaka S, Asayama N, Shigita K, Hayashi N, Oka S and Chayama K. Towards safer and appropriate application of endoscopic submucosal dissection for T1 colorectal carcinoma as total excisional biopsy: Future perspectives. *Dig Endosc.* 2014; in press.
- (30) Aoyama T, Oka S, Aikata H, Igawa A, Nakano M, Naeshiro N, Yoshida S, Tanaka S and Chayama K. Major predictors of portal hypertensive enteropathy in patients with liver cirrhosis. *J Gastroenterol Hepatol.* 2014; in press.
- (31) Sanomura Y, Oka S, Tanaka S, Numata N, Higashiyama M, Kanao H, Yoshida S, Ueno Y and Chayama K. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. *Gastric Cancer.* 2014; 17: 489–496.
- (32) Oka S, Tanaka S and Chayama K. Detection of nonpolypoid colorectal neoplasia using magnifying endoscopy in colonic inflammatory bowel disease. *Gastrointest Endosc Clin N Am.* 2014; 24: 405–417.
- (33) Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A and Japan Study Group of N. The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. *J Gastroenterol.* 2014; 49: 1163–1174.
- (34) Naeshiro N, Kakizawa H, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Ishikawa M, Awai K and Chayama K. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. *Hepatol Res.* 2014; 44: 740–749.
- (35) Honda Y, Kimura T, Aikata H, Nakahara T, Naeshiro N, Tanaka M, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Ishikawa M, Kakizawa H, Kenjo M, Awai K, Nagata Y and Chayama K. Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. *Hepatogastroenterology.* 2014; 61: 31–36.
- (36) McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H and Kumada H. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. *Antivir Ther.* 2014; 19: 479–90.
- (37) Honda Y, Takahashi S, Zhang Y, Ono A, Murakami E, Shi N, Kawaoka T, Miki D, Tsuge M, Hiraga N, Abe H, Ochi H, Imamura M, Aikata H and Chayama K. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. *J Gastroenterol Hepatol.* 2014; in press.

- (38) Tanimine N, Tanaka Y, Kobayashi T, Tashiro H, Miki D, Imamura M, Aikata H, Tanaka J, **Chayama K** and Ohdan H. Quantitative effect of natural killer cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy. *Cancer Immunol Res.* 2014; 2: 1142–7.
- (39) **Leong CR, Oshiumi H, Okamoto M, Azuma M, Takaki H, Matsumoto M, Chayama K and Seya T. A MAVS/TICAM-1-Independent Interferon-Inducing Pathway Contributes to Regulation of Hepatitis B Virus Replication in the Mouse Hydrodynamic Injection Model. J Innate Immun. 2014; in press.**
- (40) Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, **Chayama K**, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A and Jsg-Nafld TO. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. *World J Gastroenterol.* 2014; 20: 10108–10114.
- (41) Yokoyama S, Kawakami Y, Imamura M, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H and **Chayama K**. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis. *J Gastroenterol Hepatol.* 2014; in press.
- (42) Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H and **Chayama K**. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. *Hepatol Res.* 2014; in press.
- (43) **Huang YW, Takahashi S, Tsuge M, Chen CL, Wang TC, Abe H, Hu JT, Chen DS, Yang SS, Chayama K and Kao JH. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther. 2014; in press.**
- (44) Numata N, Oka S, Tanaka S, Kagemoto K, Sanomura Y, Yoshida S, Arihiro K, Shimamoto F and **Chayama K**. Risk factors and management of positive horizontal margin in early gastric cancer resected by en bloc endoscopic submucosal dissection. *Gastric Cancer.* 2014; in press.
- (45) Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, Kobayashi T, Ono A, Nakahara T, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Takahashi S, Hayes CN, Ochi H, **Chayama K** and Hiroshima Liver Study G. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis G. *Hepatol Res.* 2014; in press.
- (46) Oka S, Tanaka S, Nakadoi K, Asayama N and **Chayama K**. Endoscopic features and management of diminutive colorectal submucosal invasive carcinoma. *Dig Endosc.* 2014; 26 Suppl 2: 78–83.
- (47) Abe H, Hayes CN and **Chayama K**. New insight into the enhanced effect of pegylated interferon-alpha. *Hepatology.* 2014; 60: 1435–1437.
- (48) **Kohno T, Tsuge M, Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, Hayes CN and Chayama K. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA. J Viral Hepat. 2014; 21: e89–97.**
- (49) Minami T, Sasaki T, Serikawa M, Ishigaki T, Murakami Y and **Chayama K**. Antibiotic prophylaxis for endoscopic retrograde cholangiopancreatography increases the detection rate of drug-resistant bacteria in

- bile. *J Hepatobiliary Pancreat Sci.* 2014; 21: 712–718.
- (50) Kitamura Y, Ito M, Matsuo T, Boda T, Oka S, Yoshihara M, Tanaka S and **Chayama K**. Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful *Helicobacter pylori* eradication therapy. *Helicobacter.* 2014; 19: 289–295.
- (51) Kagemoto K, Oka S, Tanaka S, Miwata T, Urabe Y, Sanomura Y, Yoshida S, Hiyama T, Arihiro K and **Chayama K**. Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. *Gastrointest Endosc.* 2014; 80: 239–245.
- (52) Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K, Sekine A, **Chayama K**, Nakajima A and Hotta K. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. *Endocr J.* 2014; 61: 683–689.
- (53) Terasaki M, Tanaka S, Shigita K, Asayama N, Nishiyama S, Hayashi N, Nakadoi K, Oka S and **Chayama K**. Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. *Int J Colorectal Dis.* 2014; 29: 877–882.
- (54) Maruhashi T, Nakashima A, Matsumoto T, Oda N, Iwamoto Y, Iwamoto A, Kajikawa M, Kihara Y, **Chayama K**, Goto C, Noma K and Higashi Y. Relationship between nitroglycerine-induced vasodilation and clinical severity of peripheral artery disease. *Atherosclerosis.* 2014; 235: 65–70.
- (55) Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, **Chayama K**, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H and Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. *Hepatology.* 2014; 59: 2083–2091.
- (56) Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K, Sekine A, **Chayama K**, Nakajima A and Hotta K. Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. *J Hum Genet.* 2014; 59: 241–246.
- (57) Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F and **Chayama K**. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. *Antimicrob Agents Chemother.* 2014; 58: 2105–2112.
- (58) Kajikawa M, Noma K, Maruhashi T, Mikami S, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, **Chayama K**, Nakashima A, Goto C, Liao JK and Higashi Y. Rho-associated kinase activity is a predictor of cardiovascular outcomes. *Hypertension.* 2014; 63: 856–864.
- (59) Nakadoi K, Oka S, Tanaka S, Hayashi N, Terasaki M, Arihiro K, Shimamoto F and **Chayama K**. Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma. *Surg Endosc.* 2014; 28: 1269–1276.
- (60) Nishiyama S, Oka S, Tanaka S, Hayashi N, Hayashi R, Nagai K, Ueno Y, Shimamoto F, Arihiro K and **Chayama K**. Is it possible to discriminate between neoplastic and nonneoplastic lesions in ulcerative colitis by magnifying colonoscopy? *Inflamm Bowel Dis.* 2014; 20: 508–513.
- (61) Hayashi N, Tanaka S, Nishiyama S, Terasaki M, Nakadoi K, Oka S, Yoshihara M and **Chayama K**. Predictors

of incomplete resection and perforation associated with endoscopic submucosal dissection for colorectal tumors. *Gastrointest Endosc.* 2014; 79: 427–435.

- (62) Ishigaki T, Sasaki T, Serikawa M, Minami T, Okazaki A, Yukutake M, Ishii Y, Kosaka K, Mouri T, Yoshimi S and **Chayama K**. A comparative study of 4 Fr versus 6 Fr nasobiliary drainage catheters: a randomized, controlled trial. *J Gastroenterol Hepatol.* 2014; 29: 653–659.
- (63) Aoyama T, Oka S, Aikata H, Nakano M, Watari I, Naeshiro N, Yoshida S, Tanaka S and **Chayama K**. Is small-bowel capsule endoscopy effective for diagnosis of esophagogastric lesions related to portal hypertension? *J Gastroenterol Hepatol.* 2014; 29: 511–516.
- (64) Ishikawa M, Yamagami T, Kakizawa H, Hieda M, Toyota N, Fukumoto W, Kajiwara K, Yoshimatsu R, Aikata H, **Chayama K** and Awai K. Transarterial therapy of hepatocellular carcinoma fed by the right renal capsular artery. *J Vasc Interv Radiol.* 2014; 25: 389–395.
- (65) Abe H, Kimura A, Tsuruta S, Fukaya T, Sakaguchi R, Morita R, Sekiya T, Shichita T, **Chayama K**, Fujii-Kuriyama Y and Yoshimura A. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN- $\gamma$  expression and inducing IL-22. *Int Immunol.* 2014; 26: 129–137.
- (66) Takaki S, Kawakami Y, Miyaki D, Nakahara T, Naeshiro N, Murakami E, Tanaka M, Honda Y, Yokoyama S, Nagaoki Y, Kawaoka T, Hiramatsu A, Tsuge M, Hiraga N, Imamura M, Hyogo H, Aikata H, Takahashi S, Arihiro K and **Chayama K**. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. *Hepatol Res.* 2014; 44: 280–287.
- (67) Takahashi Y, Ando M, Nishikawa M, Hiraga N, Imamura M, **Chayama K** and Takakura Y. Long-term elimination of hepatitis C virus from human hepatocyte chimeric mice after interferon- $\gamma$  gene transfer. *Hum Gene Ther Clin Dev.* 2014; 25: 28–39.
- (68) Miyaki R, Yoshida S, Tanaka S, Kominami Y, Sanomura Y, Matsuo T, Oka S, Raytchev B, Tamaki T, Koide T, Kaneda K, Yoshihara M and **Chayama K**. A Computer System to Be Used With Laser-based Endoscopy for Quantitative Diagnosis of Early Gastric Cancer. *J Clin Gastroenterol.* 2014; in press.
- (69) Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H and **Chayama K**. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib. *Hepatol Res.* 2014; in press.
- (70) Kajikawa M, Nakashima A, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, **Chayama K**, Goto C, Taguchi A, Noma K and Higashi Y. Poor oral health, that is, decreased frequency of tooth brushing, is associated with endothelial dysfunction. *Circ J.* 2014; 78: 950–954.
- (71) Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S and **Chayama K**. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. *Helicobacter.* 2014; 19: 41647.
- (72) Yokoyama S, Kawakami Y and **Chayama K**. Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV. *Aliment Pharmacol Ther.* 2014; 39: 443–444.
- (73) Hyogo H, Yamagishi S, Maeda S, Fukami K, Ueda S, Okuda S, Nakahara T, Kimura Y, Ishitobi T and **Chayama**

- K.** Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. *Clin Exp Med.* 2014; 14: 45–51.
- (74) Oka S, Tanaka S, Higashiyama M, Numata N, Sanomura Y, Yoshida S, Arihiro K and **Chayama K.** Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-term outcomes. *Surg Endosc.* 2014; 28: 639–647.
- (75) Suzuki F, Toyota J, Ikeda K, **Chayama K,** Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Hu W, McPhee F, Hughes EA and Kumada H. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. *Antivir Ther.* 2014; 19: 491–9.
- (76) Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H and **Chayama K.** Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. *Hepatol Res.* 2014; 44: 1259–64.
- (77) Ohishi W, Cologne JB, Fujiwara S, Suzuki G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M and **Chayama K.** Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. *Int J Cancer.* 2014; 134: 154–163.
- (78) Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Mouri T, Yoshimi S, Shimizu A, Tsuboi T, Tanitame K and **Chayama K.** Timing of radiological improvement after steroid therapy in patients with autoimmune pancreatitis. *Scand J Gastroenterol.* 2014; 49: 727–733.
- (79) Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, Ishigaki T, Fujimoto Y, Hatta Y, Kitamura S and **Chayama K.** The effect of respiratory-gated positron emission tomography/computed tomography in patients with pancreatic cancer. *Hell J Nucl Med.* 2014; 17: 31–36.
- (80) Boda T, Ito M, Oka S, Kitamura Y, Numata N, Sanomura Y, Matsuo T, Tanaka S, Yoshihara M, Arihiro K and **Chayama K.** Characteristics of metachronous gastric tumors after endoscopic submucosal dissection for gastric intraepithelial neoplasms. *Gastroenterol Res Pract.* 2014; 2014: 863595.
- (81) Hyogo H, **Chayama K** and Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. *Curr Pharm Des.* 2014; 20: 2403–2411.
- (82) **Sakuma T, Nishikawa A, Kume S, Chayama K and Yamamoto T.** Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. *Sci Rep.* 2014; 4: 5400.
- (83) Watari I, Oka S, Tanaka S, Igawa A, Nakano M, Aoyama T, Yoshida S and **Chayama K.** Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. *Digestion.* 2014; 89: 225–231.
- (84) Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H and **Chayama K.** Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-alpha2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. *Antivir Ther.* 2014; 19: 277–285.
- (85) Ishida M, Ishida T, Tashiro S, Uchida H, Sakai C, Hironobe N, Miura K, Hashimoto Y, Arihiro K, **Chayama K,** Kihara Y and Yoshizumi M. Smoking cessation reverses DNA double-strand breaks in human mononuclear cells. *PLoS One.* 2014; 9: e103993.
- (86) Maruhashi T, Noma K, Iwamoto Y, Iwamoto A, Oda N, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y,

- Chayama K**, Nakashima A, Goto C, Liao JK and Higashi Y. Critical Role of Exogenous Nitric Oxide in ROCK Activity in Vascular Smooth Muscle Cells. *PLoS One*. 2014; 9: e109017.
- (87) Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, **Chayama K**, Okanoue T and Japan Study Group of Nonalcoholic Fatty Liver D. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. *J Gastroenterol*. 2014; 49: 1477–84.
- (88) Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, **Chayama K**, Saibara T, Anzai K, Eguchi Y and the Japan Study Group of Non-alcoholic Fatty Liver D. Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. *Hepatol Res*. 2014; 44: 11: 1196–207.
- (89) Mori N, Imamura M, Takaki S, Araki T, Hayes NC, Aisaka Y, Chayama K. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. *Intern Med*. 2014; 53: 2689–93.
- (90) Abe H, Hayes CN, Hiraga N, Imamura M, Tsuge M, Miki D, Takahashi S, Ochi H and **Chayama K**. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. *Am J Gastroenterol*. 2013; 108: 1464–1472.
- (91) Hayashi N, Tanaka S, Kanao H, Oka S, Yoshida S and **Chayama K**. Relationship between narrow-band imaging magnifying observation and pit pattern diagnosis in colorectal tumors. *Digestion*. 2013; 87: 53–58.
- (92) Lo PH, Urabe Y, Kumar V, Tanikawa C, Koike K, Kato N, Miki D, **Chayama K**, Kubo M, Nakamura Y and Matsuda K. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. *PLoS One*. 2013; 8: e61279.
- (93) Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Mullhaupt B, Negro F, Semela D, Kutalik Z, Muller T, Spengler U, Berg T, **Chayama K**, Moradpour D, Bochud PY, Hiroshima Liver Study G and Swiss Hepatitis CCSG. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PLoS One*. 2013; 8: e64053.
- (94) Mikami S, Nakashima A, Nakagawa K, Maruhashi T, Iwamoto Y, Kajikawa M, Matsumoto T, Kihara Y, **Chayama K**, Noma K, Ochi M, Nishimura M, Tsuji K, Kato Y, Goto C and Higashi Y. Autologous bone-marrow mesenchymal stem cell implantation and endothelial function in a rabbit ischemic limb model. *PLoS One*. 2013; 8: e67739.
- (95) Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, Ishikawa Y, Nagata Y, Munekage K, Ochi T, Hirose A, Nozaki-Fujimura Y, Noguchi S, Okamoto N, **Chayama K**, Suganuma N and Saibara T. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. *PLoS One*. 2013; 8: e76161.
- (96) Maruhashi T, Nakashima A, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, **Chayama K**, Goto C, Noma K, Tomiyama H, Takase B, Yamashina A and Higashi Y. Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. *BMJ Open*. 2013; 3: e003659.
- (97) Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H,

- Chayama K**, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y and Kudo M. Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. *Dig Dis*. 2013; 31: 472–479.
- (98) Miki D, Ochi H, Takahashi A, Hayes CN, Urabe Y, Abe H, Kawaoka T, Tsuge M, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Akuta N, Suzuki F, Ikeda K, Kumada H, Karino Y, Toyota J, Tsunoda T, Kubo M, Kamatani N, Nakamura Y and **Chayama K**. HLA-DQB1\*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. *PLoS One*. 2013; 8: e84226.
- (99) Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, **Chayama K**, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR and Ichida T. Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. *Intern Med*. 2013; 52: 2701–2706.
- (100) Watari I, Oka S, Tanaka S, Nakano M, Aoyama T, Yoshida S and **Chayama K**. Is Occult Obscure Gastrointestinal Bleeding a Definite Indication for Capsule Endoscopy? A Retrospective Analysis of Diagnostic Yield in Patients with Occult versus Overt Bleeding. *Gastroenterol Res Pract*. 2013; 2013: 91:5463.
- (101) Fukuhara T, Kakizawa H, Aikata H, Tani C, Ishikawa M, Awai K and **Chayama K**. Usefulness of multi-detector row computed tomography for management of duodenal varices by emergency balloon-occluded retrograde transvenous obliteration. *Clinical Journal of Gastroenterology*. 2013; 6: 243–247.
- (102) Hyogo H, Yamagishi S-i, Maeda S, Nakahara T, Kimura Y and **Chayama K**. sRAGE is associated with low waist circumference and Hb levels in NAFLD. *Central European Journal of Medicine*. 2013; 8: 830–834.
- (103) Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, **Chayama K** and Hiroshima Liver Study G. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. *J Gastroenterol*. 2013; in press.
- (104) Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, Fukuhara T, Kobayashi T, Naeshiro N, Nakahara T, Kawaoka T, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K and **Chayama K**. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. *J Gastroenterol Hepatol*. 2013; 28: 1834–1841.
- (105) Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, **Chayama K**, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Yamashina A and Higashi Y. Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study. *Heart*. 2013; 99: 1837–1842.
- (106) Onoyama M, Kitadai Y, Tanaka Y, Yuge R, Shinagawa K, Tanaka S, Yasui W and **Chayama K**. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. *Neoplasia*.

2013; 15: 1391–1399.

- (107) **Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T and Chayama K.** A novel TK–NOG based humanized mouse model for the study of HBV and HCV infections. *Biochem Biophys Res Commun.* 2013; 441: 230–235.
- (108) Furusho H, Miyauchi M, Hyogo H, Inubushi T, Ao M, Ouhara K, Hisatune J, Kurihara H, Sugai M, Hayes CN, Nakahara T, Aikata H, Takahashi S, **Chayama K** and Takata T. Dental infection of Porphyromonas gingivalis exacerbates high fat diet–induced steatohepatitis in mice. *J Gastroenterol.* 2013; 48: 1259–1270.
- (109) Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K and **Chayama K.** Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. *Hepatol Res.* 2013; 43: 1182–1189.
- (110) Miwata T, Hiyama T, Oka S, Tanaka S, Shimamoto F, Arihiro K and **Chayama K.** Clinicopathologic features of hyperplastic/serrated polyposis syndrome in Japan. *J Gastroenterol Hepatol.* 2013; 28: 1693–1698.
- (111) **Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H and Chayama K.** Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. *J Gastroenterol.* 2013; 48: 1188–1204.
- (112) Ishii Y, Sasaki T, Serikawa M, Minami T, Okazaki A, Yukutake M, Ishigaki T, Kosaka K, Mouri T, Yoshimi S, Shimizu A, Tsuboi T and **Chayama K.** Elevated expression of cyclooxygenase–2 and microsomal prostaglandin E synthase–1 in primary sclerosing cholangitis: implications for cholangiocarcinogenesis. *Int J Oncol.* 2013; 43: 1073–1079.
- (113) Numata N, Oka S, Tanaka S, Higashiyama M, Sanomura Y, Yoshida S, Arihiro K and **Chayama K.** Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in patients with chronic kidney disease. *J Gastroenterol Hepatol.* 2013; 28: 1632–1637.
- (114) Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, **Chayama K** and Hijikata M. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. *Gastroenterology.* 2013; 145: 658–667 e611.
- (115) Nakano M, Oka S, Tanaka S, Aoyama T, Watari I, Hayashi R, Miyaki R, Nagai K, Sanomura Y, Yoshida S, Ueno Y and **Chayama K.** Clinical usefulness of classification by transabdominal ultrasonography for detection of small–bowel stricture. *Scand J Gastroenterol.* 2013; 48: 1041–1047.
- (116) Ozawa S, Tanaka S, Hayashi N, Nishiyama S, Terasaki M, Nakadoi K, Kanao H, Oka S, Yoshida S and **Chayama K.** Risk factors for vertical incomplete resection in endoscopic submucosal dissection as total excisional biopsy for submucosal invasive colorectal carcinoma. *Int J Colorectal Dis.* 2013; 28: 1247–1256.
- (117) Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, Saibara T, **Chayama K,** Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A and Japan Study Group of Nonalcoholic Fatty Liver D. Noninvasive scoring systems in patients

- with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. *J Gastroenterol.* 2013; 48: 1051–1060.
- (118) Igawa A, Oka S, Tanaka S, Nakano M, Aoyama T, Watari I, Aikata H, Arihiro K and **Chayama K**. Small bowel metastasis of hepatocellular carcinoma detected by capsule endoscopy. *Case Rep Gastroenterol.* 2013; 7: 492–497.
- (119) Imada S, Ishiyama K, Ide K, Kobayashi T, Amano H, Tashiro H, Arihiro K, Aikata H, **Chayama K** and Ohdan H. Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma. *World J Surg Oncol.* 2013; 11: 177.
- (120) Idei N, Ukawa T, Kajikawa M, Iwamoto Y, Fujimura N, Maruhashi T, Mikami S, Matsumoto T, Kihara Y, **Chayama K**, Noma K, Nakashima A, Takayanagi T, Morimoto H, Tsuji T and Higashi Y. A novel noninvasive and simple method for assessment of endothelial function: enclosed zone flow-mediated vasodilation (ezFMD) using an oscillation amplitude measurement. *Atherosclerosis.* 2013; 229: 324–330.
- (121) Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T, Yoshida S and **Chayama K**. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. *BMC Gastroenterol.* 2013; 13: 108.
- (122) Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M and **Chayama K**. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. *Gut.* 2013; 62: 1055–1061.
- (123) Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, **Chayama K**, Nakajima A, Nakao K, Sekine A and Hotta K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. *Hum Genet.* 2013; 132: 783–792.
- (124) Kimura T, Takahashi S, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y, Doi Y, Kaneyasu Y, Murakami Y, Honda Y, Aikata H, **Chayama K** and Nagata Y. Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects? *Hepatol Res.* 2013; 43: 717–727.
- (125) Higashimaya M, Oka S, Tanaka S, Sanomura Y, Yoshida S, Hiyama T, Arihiro K, Shimamoto F and **Chayama K**. Outcome of endoscopic submucosal dissection for gastric neoplasm in relationship to endoscopic classification of submucosal fibrosis. *Gastric Cancer.* 2013; 16: 404–410.
- (126) Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H and **Chayama K**. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. *J Gastroenterol.* 2013; 48: 847–855.
- (127) Tsuge M and **Chayama K**. Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy. *J Gastroenterol.* 2013; 48: 779–780.
- (128) Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y,

- Chayama K**, Noma K, Nakashima A, Goto C and Higashi Y. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. *Arterioscler Thromb Vasc Biol.* 2013; 33: 1401–1408.
- (129) Kuwabara T, Hiyama T, Oka S, Urabe Y, Tanaka S, Yoshihara M, Arihiro K, Shimamoto F and **Chayama K**. Response. *Gastrointest Endosc.* 2013; 77: 973–974.
- (130) Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, So R, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, **Chayama K**, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Sakata T, Tanaka K, Matsuzawa Y, Nakao K, Sekine A and Hotta K. NUDT3 rs206936 is associated with body mass index in obese Japanese women. *Endocr J.* 2013; 60: 991–1000.
- (131) Miyaki R, Yoshida S, Tanaka S, Kominami Y, Sanomura Y, Matsuo T, Oka S, Raytchev B, Tamaki T, Koide T, Kaneda K, Yoshihara M and **Chayama K**. Quantitative identification of mucosal gastric cancer under magnifying endoscopy with flexible spectral imaging color enhancement. *J Gastroenterol Hepatol.* 2013; 28: 841–847.
- (132) Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PH, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, **Chayama K**, Nakamura Y and Matsuda K. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. *J Hepatol.* 2013; 58: 875–882.
- (133) **Arataki K, Hayes CN, Akamatsu S, Akiyama R, Abe H, Tsuge M, Miki D, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami H, Ohishi W and Chayama K. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol.** 2013; 85: 789–798.
- (134) Oka S, Tanaka S, Nakadoi K, Kanao H and **Chayama K**. Risk analysis of submucosal invasive rectal carcinomas for lymph node metastasis to expand indication criteria for endoscopic resection. *Dig Endosc.* 2013; 25 Suppl 2: 21–25.
- (135) Aoyama T, Oka S, Aikata H, Nakano M, Watari I, Naeshiro N, Yoshida S, Tanaka S and **Chayama K**. Small bowel abnormalities in patients with compensated liver cirrhosis. *Dig Dis Sci.* 2013; 58: 1390–1396.
- (136) Suenari K, Nakano Y, Hirai Y, Ogi H, Oda N, Makita Y, Ueda S, Kajihara K, Tokuyama T, Motoda C, Fujiwara M, **Chayama K** and Kihara Y. Left atrial thickness under the catheter ablation lines in patients with paroxysmal atrial fibrillation: insights from 64-slice multidetector computed tomography. *Heart Vessels.* 2013; 28: 360–368.
- (137) Hotta K, Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, So R, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, **Chayama K**, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Sakata T, Tanaka K, Matsuzawa Y, Nakao K and Sekine A. Replication study of 15 recently published Loci for body fat distribution in the Japanese population. *J Atheroscler Thromb.* 2013; 20: 336–350.
- (138) Saibara T, Enomoto N, Kaneko S, **Chayama K**, Sata M, Imawari M, Onishi S and Okita K. Clinical efficacy of combination therapy with ME3738 and pegylated interferon- $\alpha$ -2a in patients with hepatitis C virus

- genotype 1. *Hepatol Res.* 2013; in press.
- (139) Ishitobi T, Hyogo H, Tokumo H, Arihiro K and **Chayama K**. Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. *Hepatol Res.* 2013; in press.
- (140) Hamai Y, Hihara J, Aoki Y, Taomoto J, Kishimoto I, Kobayashi Y, Miyata Y, Aikata H, **Chayama K** and Okada M. Airway stenting for tracheal obstruction due to lymph node metastasis of hepatocellular carcinoma. *Anticancer Res.* 2013; 33: 1761–1764.
- (141) Nakano Y, **Chayama K**, Ochi H, Toshishige M, Hayashida Y, Miki D, Hayes CN, Suzuki H, Tokuyama T, Oda N, Suenari K, Uchimura-Makita Y, Kajihara K, Sairaku A, Motoda C, Fujiwara M, Watanabe Y, Yoshida Y, Ohkubo K, Watanabe I, Nogami A, Hasegawa K, Watanabe H, Endo N, Aiba T, Shimizu W, Ohno S, Horie M, Arihiro K, Tashiro S, Makita N and Kihara Y. A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillation. *PLoS Genet.* 2013; 9: e1003364.
- (142) Takata S, Tanaka S, Hayashi N, Terasaki M, Nakadoi K, Kanao H, Oka S, Yoshida S and **Chayama K**. Characteristic magnifying narrow-band imaging features of colorectal tumors in each growth type. *Int J Colorectal Dis.* 2013; 28: 459–468.
- (143) Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, **Chayama K**, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E and Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. *J Hepatol.* 2013; 58: 655–662.
- (144) Karino Y, Toyota J, Ikeda K, Suzuki F, **Chayama K**, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F and Kumada H. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. *J Hepatol.* 2013; 58: 646–654.
- (145) **Chayama K**, Hayes CN, Ohishi W and Kawakami Y. Response to “treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle?’”. *J Gastroenterol.* 2013; 48: 557–558.
- (146) Fujii Y, Teragawa H, Soga J, Idei N, Fujimura N, Maruhashi T, Mikami S, Iwamoto Y, Hidaka T, Kihara Y, **Chayama K**, Noma K, Nakashima A, Goto C and Higashi Y. Flow-mediated vasodilation and anatomical variation of the brachial artery (double brachial artery) in healthy subjects and patients with cardiovascular disease. *Circ J.* 2013; 77: 1073–1080.
- (147) Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, **Chayama K**, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F and Kumada H. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. *J Viral Hepat.* 2013; 20: 167–173.
- (148) Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y and **Chayama K**. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2013; 28: 530–536.
- (149) Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H and **Chayama K**. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2013; 28: 565–575.
- (150) Tashiro H, Ide K, Amano H, Kobayashi T, Onoe T, Ishiyama K, Kuroda S, Tazawa H, Kono H, Aikata H, Takahashi S, **Chayama K** and Ohdan H. Surgical treatment for portosystemic encephalopathy in patients

- with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy. *Hepatol Res.* 2013; 43: 249–254.
- (151) Tanaka S, Terasaki M, Hayashi N, Oka S and **Chayama K**. Warning for unprincipled colorectal endoscopic submucosal dissection: accurate diagnosis and reasonable treatment strategy. *Dig Endosc.* 2013; 25: 107–116.
- (152) Takamura A, Ito M, Boda T, Matsumoto Y, Tanaka S, Yoshihara M and **Chayama K**. High expression of gastrin receptor protein in injured mucosa of Helicobacter pylori-positive gastritis. *Dig Dis Sci.* 2013; 58: 634–640.
- (153) Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, **Chayama K**, Yatsushashi H, Oketani M and Kumada H. Inhibition of hepatocellular carcinoma by PegIFNalpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. *J Gastroenterol.* 2013; 48: 382–390.
- (154) Tanaka S, Hayashi N, Oka S and **Chayama K**. Endoscopic assessment of colorectal cancer with superficial or deep submucosal invasion using magnifying colonoscopy. *Clin Endosc.* 2013; 46: 138–146.
- (155) Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W and **Chayama K**. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. *Int J Cancer.* 2013; 132: 813–823.
- (156) Higashimaya M, Oka S, Tanaka S, Numata N, Sanomura Y, Yoshida S, Arihiro K and **Chayama K**. Endoscopic submucosal dissection for residual early gastric cancer after endoscopic submucosal dissection. *Gastrointest Endosc.* 2013; 77: 298–302.
- (157) **Chayama K** and Hayes CN. Interleukin-28B polymorphisms and hepatitis C virus clearance. *Genome Med.* 2013; 5: 6.
- (158) Nakano R, Maekawa T, Abe H, Hayashida Y, Ochi H, Tsunoda T, Kumada H, Kamatani N, Nakamura Y and **Chayama K**. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. *J Gen Virol.* 2013; 94: 81–89.
- (159) **Chayama K**, Hayes CN, Ohishi W and Kawakami Y. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. *J Gastroenterol.* 2013; 48: 1–12.
- (160) Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K and **Chayama K**. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. *Hepatol Res.* 2012; 42: 442–453.
- (161) Yanagimoto S, Yotsuyanagi H, Kikuchi Y, Tsukada K, Kato M, Takamatsu J, Hige S, **Chayama K**, Moriya K and Koike K. Chronic hepatitis B in patients coinfecting with human immunodeficiency virus in Japan: a retrospective multicenter analysis. *J Infect Chemother.* 2012; 18: 883–890.
- (162) Kuwabara T, Hiyama T, Oka S, Urabe Y, Tanaka S, Yoshihara M, Arihiro K, Shimamoto F and **Chayama K**. Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic

- submucosal dissection. *Gastrointest Endosc.* 2012; 76: 1095–1103.
- (163) Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K and Chayama K. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child–Pugh classification. *J Gastroenterol Hepatol.* 2012; 27: 1850–1857.
- (164) Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K. Serum levels of pigment epithelium–derived factor (PEDF) are independently associated with procollagen III N–terminal peptide levels in patients with nonalcoholic fatty liver disease. *Clin Biochem.* 2012; 45: 1554–1557.
- (165) Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S and Chayama K. Efficacy of rosuvastatin for the treatment of non–alcoholic steatohepatitis with dyslipidemia: An open–label, pilot study. *Hepatol Res.* 2012; 42: 1065–1072.
- (166) Tatsugami M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K and Chayama K. Bile Acid promotes intestinal metaplasia and gastric carcinogenesis. *Cancer Epidemiol Biomarkers Prev.* 2012; 21: 2101–2107.
- (167) Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. *Dig Liver Dis.* 2012; 44: 935–939.
- (168) Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T and Sakata K. A randomized phase II trial of intra–arterial chemotherapy using SM–11355 (Miriplatin) for hepatocellular carcinoma. *Invest New Drugs.* 2012; 30: 2015–2025.
- (169) Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H and Chayama K. Interleukin–28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. *J Gastroenterol Hepatol.* 2012; 27: 1467–1472.
- (170) Chayama K, Hayes CN and Imamura M. Impact of interleukin–28B genotype on in vitro and in vivo systems of hepatitis C virus replication. *Hepatol Res.* 2012; 42: 841–853.
- (171) Iwamoto Y, Maruhashi T, Fujii Y, Idei N, Fujimura N, Mikami S, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A and Higashi Y. Intima–media thickness of brachial artery, vascular function, and cardiovascular risk factors. *Arterioscler Thromb Vasc Biol.* 2012; 32: 2295–2303.
- (172) Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H and Chayama K. Achievement of sustained viral response after switching treatment from pegylated interferon alpha–2b to alpha–2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report. *Intervirology.* 2012; 55: 306–310.
- (173) Okanobu H, Ito M, Tanaka S, Onogawa S, Akagi M, Oh EH, Nagata S, Okamoto S, Kuwai T, Cho S, Matsumoto Y, Kitamura S, Hidaka T and Chayama K. Evaluation of Individual Risk in Nonvariceal Gastrointestinal Bleeding Patients with NSAID Administration: A Multicenter Study in Japan. *Digestion.* 2012; 86: 187–193.

- (174) Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H and Chayama K. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. *Hepatology*. 2012; 56: 555–566.
- (175) Nakadoi K, Tanaka S, Hayashi N, Ozawa S, Terasaki M, Takata S, Kanao H, Oka S and Chayama K. Clinical outcomes of endoscopic submucosal dissection for rectal tumor close to the dentate line. *Gastrointest Endosc*. 2012; 76: 444–450.
- (176) Imajo K, Ueda Y, Kawano F, Sao H, Kamimura T, Ito Y, Mugitani A, Suzuki K, Uike N, Miyamura K, Uski K, Morimatsu Y, Akiyama N, Nagai H, Ohara A, Tanimoto M, Takaki K, Chayama K, Urabe M, Nagatoshi Y and Tamura K. [A phase III study of the efficacy and safety of meropenem in patients with febrile neutropenia]. *Jpn J Antibiot*. 2012; 65: 271–287.
- (177) Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A, Tomiyama H, Takase B, Yamashina A and Higashi Y. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. *Circulation*. 2012; 126: 598–603.
- (178) Kohno T, Tsuge M, Hayes CN, Hatakeyama T, Ohnishi M, Abe H, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Tanaka S and Chayama K. Identification of novel HCV deletion mutants in chronic hepatitis C patients. *Antivir Ther*. 2012; 17: 1551–1561.
- (179) Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y and Kumada H. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. *Intervirology*. 2012; 55: 231–241.
- (180) Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K and Chayama K. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. *J Gastroenterol*. 2012; 47: 834–844.
- (181) Matsuo J, Mizui M, Okita H, Katayama K, Aimitsu S, Sakata T, Obayashi M, Nakanishi T, Chayama K, Miyakawa Y, Yoshizawa H, Tanaka J and for the Hiroshima Hepatitis Study G. Follow up of the 987 blood donors found with hepatitis C virus infection over 9–18 years. *Hepatol Res*. 2012; 42: 637–647.
- (182) Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T and Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet*. 2012; 44: 760–764.
- (183) Hayes CN, Imamura M, Aikata H and Chayama K. Genetics of IL28B and HCV—response to infection and treatment. *Nat Rev Gastroenterol Hepatol*. 2012; 9: 406–417.
- (184) Kanbara A, Miura Y, Hyogo H, Chayama K and Seyama I. Effect of urine pH changed by dietary intervention

- on uric acid clearance mechanism of pH-dependent excretion of urinary uric acid. *Nutr J* 2012; 11: 39.
- (185) Shishido T, Oka S, Tanaka S, Aoyama T, Watari I, Imagawa H, Yoshida S and Chayama K. Diagnostic yield of capsule endoscopy vs. double-balloon endoscopy for patients who have undergone total enteroscopy with obscure gastrointestinal bleeding. *Hepatogastroenterology*. 2012; 59: 955–959.
- (186) Nakadoi K, Tanaka S, Kanao H, Terasaki M, Takata S, Oka S, Yoshida S, Arihiro K and Chayama K. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. *J Gastroenterol Hepatol*. 2012; 27: 1057–1062.
- (187) Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property. *Dig Liver Dis*. 2012; 44: 492–496.
- (188) Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, Takaki S, Takahashi S, Arihiro K, Chayama K and Ohdan H. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. *Transplantation*. 2012; 93: 1024–1030.
- (189) Miki D, Ochi H, Hayes CN, Aikata H and Chayama K. Hepatocellular carcinoma: towards personalized medicine. *Cancer Sci*. 2012; 103: 846–850.
- (190) Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T and Jsg N. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. *J Gastroenterol*. 2012; 47: 586–595.
- (191) Hotta K, Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, So R, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, Chayama K, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Tanaka K, Matsuzawa Y, Nakao K and Sekine A. Association between type 2 diabetes genetic susceptibility loci and visceral and subcutaneous fat area as determined by computed tomography. *J Hum Genet*. 2012; 57: 305–310.
- (192) Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y and Kumada H. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. *J Gastroenterol*. 2012; 47: 596–605.
- (193) Iiboshi T, Hanada K, Fukuda T, Yonehara S, Sasaki T and Chayama K. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer: establishing a new method for the early detection of pancreatic carcinoma in situ. *Pancreas*. 2012; 41: 523–529.
- (194) Hashimoto M, Kobayashi T, Tashiro H, Amano H, Oshita A, Tanimoto Y, Kuroda S, Tazawa H, Aikata H, Chayama K, Fujii M, Arihiro K and Ohdan H. A huge metastatic liver tumor from leiomyosarcoma of the inferior vena cava: report of a case. *Surg Today*. 2012; 42: 505–508.
- (195) Oka S, Tanaka S, Takata S, Kanao H and Chayama K. Usefulness and safety of SB knife Jr in endoscopic submucosal dissection for colorectal tumors. *Dig Endosc*. 2012; 24 Suppl 1: 90–95.
- (196) Tanaka S, Terasaki M, Kanao H, Oka S and Chayama K. Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. *Dig Endosc*. 2012; 24 Suppl 1: 73–79.

- (197) Terasaki M, Tanaka S, Oka S, Nakadoi K, Takata S, Kanao H, Yoshida S and **Chayama K**. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. *J Gastroenterol Hepatol*. 2012; 27: 734–740.
- (198) Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S and **Chayama K**. Recent trend of clinical features in patients with hepatocellular carcinoma. *Hepatol Res*. 2012; 42: 368–375.
- (199) Onji K, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Okajima M and **Chayama K**. Microvascular structure and perfusion imaging of colon cancer by means of contrast-enhanced ultrasonography. *Abdom Imaging*. 2012; 37: 297–303.
- (200) **Chayama K**, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E and Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology*. 2012; 55: 742–748.
- (201) Ohishi W and **Chayama K**. Treatment of chronic hepatitis B with nucleos(t)ide analogues. *Hepatol Res*. 2012; 42: 219–225.
- (202) Ito M, Yoshihara M, Takata S, Wada Y, Matsuo T, Boda T, Tanaka S and **Chayama K**. Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese. *J Gastroenterol Hepatol*. 2012; 27: 598–602.
- (203) Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, Kamatani N, Kohri K, **Chayama K**, Kubo M, Nakamura Y and Matsuda K. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1. *PLoS Genet*. 2012; 8: e1002541.
- (204) Shishido T, Oka S, Tanaka S, Imagawa H, Takemura Y, Yoshida S and **Chayama K**. Outcome of patients who have undergone total enteroscopy for obscure gastrointestinal bleeding. *World J Gastroenterol*. 2012; 18: 666–672.
- (205) Kuwabara T, **Chayama K**, Tanaka S, Oka S, Hiyama T and Yoshihara M. Compliance with standard precautions among gastrointestinal endoscopists and endoscopy nurses in Japan. *Am J Infect Control*. 2012; 40: 80.
- (206) Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, **Chayama K** and Ohdan H. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. *Ann Surg Oncol*. 2012; 19: 418–425.
- (207) Hayashi N, Okanoue T, Tsubouchi H, Toyota J, **Chayama K** and Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. *J Viral Hepat*. 2012; 19: e134–142.
- (208) Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y and **Chayama K**. Serum PAI-1 is a novel predictor for response to pegylated interferon- $\alpha$ -2b plus ribavirin therapy in chronic hepatitis C virus infection. *J Viral Hepat*. 2012; 19: e126–133.
- (209) Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, **Chayama K**, Alrefai WA